Global Targeted Protein Degradation Drug Market Growth (Status and Outlook) 2024-2030

Global Targeted Protein Degradation Drug Market Growth (Status and Outlook) 2024-2030

The global Targeted Protein Degradation Drug market size is projected to grow from US$ million in 2023 to US$ million in 2030; it is expected to grow at a CAGR of % from 2024 to 2030.

LPI (LP Information)' newest research report, the “Targeted Protein Degradation Drug Industry Forecast” looks at past sales and reviews total world Targeted Protein Degradation Drug sales in 2023, providing a comprehensive analysis by region and market sector of projected Targeted Protein Degradation Drug sales for 2024 through 2030. With Targeted Protein Degradation Drug sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Targeted Protein Degradation Drug industry.

This Insight Report provides a comprehensive analysis of the global Targeted Protein Degradation Drug landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Targeted Protein Degradation Drug portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Targeted Protein Degradation Drug market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Targeted Protein Degradation Drug and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Targeted Protein Degradation Drug.

United States market for Targeted Protein Degradation Drug is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.

China market for Targeted Protein Degradation Drug is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.

Europe market for Targeted Protein Degradation Drug is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.

Global key Targeted Protein Degradation Drug players cover Arvinas, Kangpu Biopharmaceuticals, Ranok Therapeutics, Accutar Biotechnology and BeiGene Ltd., etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2023.

This report presents a comprehensive overview, market shares, and growth opportunities of Targeted Protein Degradation Drug market by product type, application, key players and key regions and countries.

Segmentation by type
PROTAC
Molecular Glue

Segmentation by application
Cancer
Autoimmune Diseases
Other

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Arvinas
Kangpu Biopharmaceuticals
Ranok Therapeutics
Accutar Biotechnology
BeiGene Ltd.
Hinova Pharmaceuticals
Haisco Pharmaceutical
Nurix
Kymera Therapeutics
C4 Therapeutics

Please note: The report will take approximately 2 business days to prepare and deliver.